Sarah Faubel
Concepts (435)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Acute Kidney Injury | 82 | 2023 | 638 | 16.500 |
Why?
| Interleukin-6 | 17 | 2023 | 676 | 2.980 |
Why?
| Kidney | 22 | 2023 | 1186 | 2.660 |
Why?
| Reperfusion Injury | 8 | 2023 | 254 | 2.520 |
Why?
| Ischemia | 11 | 2021 | 363 | 2.490 |
Why?
| Acute Lung Injury | 6 | 2021 | 300 | 2.110 |
Why?
| Lung Injury | 6 | 2017 | 198 | 1.980 |
Why?
| Cardiac Surgical Procedures | 10 | 2020 | 413 | 1.850 |
Why?
| Renal Replacement Therapy | 10 | 2023 | 66 | 1.730 |
Why?
| Water-Electrolyte Imbalance | 5 | 2020 | 26 | 1.600 |
Why?
| Nephrectomy | 7 | 2021 | 150 | 1.560 |
Why?
| Mice, Inbred C57BL | 34 | 2023 | 4718 | 1.560 |
Why?
| Cardio-Renal Syndrome | 2 | 2023 | 10 | 1.520 |
Why?
| Sepsis | 9 | 2020 | 509 | 1.520 |
Why?
| Cytokines | 14 | 2021 | 1843 | 1.320 |
Why?
| Interleukin-10 | 6 | 2017 | 297 | 1.290 |
Why?
| Creatinine | 11 | 2020 | 425 | 1.200 |
Why?
| Pneumonia | 4 | 2021 | 568 | 1.150 |
Why?
| Postoperative Complications | 9 | 2020 | 2150 | 1.110 |
Why?
| Mice | 44 | 2023 | 14928 | 1.030 |
Why?
| Biomarkers | 18 | 2023 | 3419 | 1.010 |
Why?
| Caspase 1 | 11 | 2014 | 140 | 1.010 |
Why?
| Interleukin-18 | 10 | 2019 | 219 | 1.000 |
Why?
| Oxidative Stress | 2 | 2021 | 1085 | 0.910 |
Why?
| Metabolome | 3 | 2021 | 285 | 0.900 |
Why?
| Lipocalins | 3 | 2019 | 35 | 0.900 |
Why?
| Azotemia | 1 | 2023 | 6 | 0.890 |
Why?
| Lipocalin-2 | 7 | 2023 | 62 | 0.870 |
Why?
| Disease Models, Animal | 16 | 2023 | 3545 | 0.830 |
Why?
| Body Fluids | 2 | 2020 | 58 | 0.820 |
Why?
| Animals | 54 | 2023 | 31868 | 0.810 |
Why?
| Cardiopulmonary Bypass | 3 | 2019 | 176 | 0.800 |
Why?
| Intensive Care Units | 8 | 2021 | 620 | 0.790 |
Why?
| Tissue Inhibitor of Metalloproteinase-2 | 4 | 2019 | 12 | 0.790 |
Why?
| Kidney Function Tests | 2 | 2019 | 141 | 0.750 |
Why?
| Insulin-Like Growth Factor Binding Proteins | 3 | 2018 | 24 | 0.740 |
Why?
| Nephrologists | 2 | 2017 | 12 | 0.730 |
Why?
| Hospital Mortality | 9 | 2020 | 777 | 0.730 |
Why?
| Cisplatin | 7 | 2016 | 262 | 0.710 |
Why?
| Urokinase-Type Plasminogen Activator | 1 | 2020 | 28 | 0.710 |
Why?
| Critical Illness | 9 | 2023 | 645 | 0.710 |
Why?
| Heart Diseases | 2 | 2023 | 330 | 0.700 |
Why?
| Peritoneal Dialysis | 2 | 2018 | 83 | 0.660 |
Why?
| Systemic Inflammatory Response Syndrome | 2 | 2017 | 71 | 0.660 |
Why?
| Renal Dialysis | 6 | 2021 | 369 | 0.660 |
Why?
| Adenosine Triphosphate | 2 | 2021 | 431 | 0.650 |
Why?
| Heart Failure, Diastolic | 1 | 2019 | 20 | 0.640 |
Why?
| Pulmonary Edema | 1 | 2019 | 116 | 0.620 |
Why?
| Kidney Diseases | 5 | 2021 | 350 | 0.620 |
Why?
| Chemokine CXCL1 | 6 | 2012 | 66 | 0.600 |
Why?
| Lung | 7 | 2023 | 3595 | 0.590 |
Why?
| Male | 53 | 2023 | 55737 | 0.580 |
Why?
| Glomerular Filtration Rate | 6 | 2023 | 604 | 0.580 |
Why?
| Humans | 67 | 2023 | 115052 | 0.570 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2017 | 965 | 0.560 |
Why?
| Critical Care | 4 | 2021 | 476 | 0.550 |
Why?
| Interleukin-1beta | 6 | 2014 | 370 | 0.550 |
Why?
| Nephrology | 3 | 2016 | 48 | 0.550 |
Why?
| Proteinuria | 3 | 2019 | 77 | 0.530 |
Why?
| Peroxidase | 6 | 2017 | 157 | 0.530 |
Why?
| Spectroscopy, Near-Infrared | 1 | 2016 | 47 | 0.530 |
Why?
| Hyperkalemia | 1 | 2016 | 26 | 0.520 |
Why?
| Kidney Tubular Necrosis, Acute | 4 | 2015 | 22 | 0.520 |
Why?
| Models, Animal | 1 | 2017 | 348 | 0.500 |
Why?
| Containment of Biohazards | 1 | 2015 | 11 | 0.500 |
Why?
| Acidosis | 1 | 2016 | 87 | 0.490 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 21 | 0.490 |
Why?
| Hemorrhagic Fever, Ebola | 1 | 2015 | 33 | 0.480 |
Why?
| Losartan | 1 | 2014 | 9 | 0.480 |
Why?
| Caspase Inhibitors | 6 | 2014 | 78 | 0.480 |
Why?
| Lisinopril | 1 | 2014 | 14 | 0.480 |
Why?
| Respiration, Artificial | 4 | 2018 | 526 | 0.480 |
Why?
| Neutrophil Infiltration | 4 | 2012 | 94 | 0.470 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 29 | 0.470 |
Why?
| Chlorides | 3 | 2020 | 127 | 0.460 |
Why?
| Thrombocytopenia | 3 | 2021 | 178 | 0.450 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2013 | 1138 | 0.450 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 180 | 0.440 |
Why?
| Early Medical Intervention | 1 | 2013 | 51 | 0.430 |
Why?
| Ultrasonography, Doppler | 1 | 2013 | 105 | 0.430 |
Why?
| Severity of Illness Index | 5 | 2014 | 2551 | 0.430 |
Why?
| Apoptosis | 10 | 2019 | 2366 | 0.410 |
Why?
| Interleukin-8 | 2 | 2013 | 238 | 0.410 |
Why?
| Developing Countries | 1 | 2013 | 236 | 0.400 |
Why?
| Acute-Phase Proteins | 3 | 2019 | 64 | 0.390 |
Why?
| Energy Metabolism | 3 | 2021 | 729 | 0.380 |
Why?
| Diagnostic Imaging | 1 | 2014 | 290 | 0.380 |
Why?
| Kidney Tubules, Proximal | 2 | 2014 | 113 | 0.380 |
Why?
| Splenectomy | 1 | 2011 | 53 | 0.380 |
Why?
| Kidney Failure, Chronic | 4 | 2019 | 489 | 0.360 |
Why?
| Antibodies, Monoclonal | 2 | 2013 | 1268 | 0.330 |
Why?
| Hepatocytes | 2 | 2020 | 196 | 0.320 |
Why?
| Multiple Organ Failure | 1 | 2009 | 142 | 0.320 |
Why?
| Macrophages, Alveolar | 1 | 2011 | 351 | 0.310 |
Why?
| Uremia | 1 | 2008 | 14 | 0.310 |
Why?
| Antineoplastic Agents | 5 | 2016 | 1879 | 0.310 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2019 | 1215 | 0.300 |
Why?
| Mice, Knockout | 9 | 2021 | 2585 | 0.300 |
Why?
| Time Factors | 8 | 2019 | 6142 | 0.290 |
Why?
| Endothelial Cells | 6 | 2019 | 685 | 0.290 |
Why?
| Inflammation Mediators | 5 | 2021 | 476 | 0.290 |
Why?
| Inflammation | 5 | 2019 | 2485 | 0.280 |
Why?
| Endotoxins | 3 | 2013 | 205 | 0.270 |
Why?
| Female | 28 | 2022 | 59619 | 0.260 |
Why?
| Prospective Studies | 5 | 2023 | 6232 | 0.260 |
Why?
| Respiratory Insufficiency | 2 | 2011 | 290 | 0.260 |
Why?
| Blood Urea Nitrogen | 4 | 2013 | 51 | 0.260 |
Why?
| Delayed Graft Function | 1 | 2005 | 26 | 0.250 |
Why?
| Necrosis | 4 | 2014 | 210 | 0.250 |
Why?
| Risk Factors | 12 | 2021 | 8642 | 0.250 |
Why?
| Lymphocyte Depletion | 1 | 2005 | 116 | 0.250 |
Why?
| Lung Diseases | 2 | 2009 | 703 | 0.250 |
Why?
| Macrophages | 6 | 2021 | 1267 | 0.250 |
Why?
| Clinical Trials as Topic | 4 | 2016 | 937 | 0.240 |
Why?
| Infant, Newborn | 7 | 2023 | 5040 | 0.240 |
Why?
| Caspases | 7 | 2013 | 245 | 0.240 |
Why?
| Autophagy | 2 | 2021 | 234 | 0.240 |
Why?
| Heart Failure | 2 | 2019 | 1962 | 0.240 |
Why?
| Intensive Care Units, Pediatric | 4 | 2020 | 147 | 0.230 |
Why?
| Predictive Value of Tests | 3 | 2014 | 1812 | 0.230 |
Why?
| Retrospective Studies | 13 | 2023 | 12548 | 0.230 |
Why?
| Hepcidins | 1 | 2023 | 21 | 0.220 |
Why?
| Infant | 6 | 2018 | 7946 | 0.220 |
Why?
| Acute-Phase Reaction | 1 | 2023 | 39 | 0.220 |
Why?
| Furosemide | 1 | 2023 | 32 | 0.220 |
Why?
| Cell Membrane | 1 | 2007 | 681 | 0.220 |
Why?
| Caspase 3 | 8 | 2011 | 237 | 0.220 |
Why?
| Child, Preschool | 7 | 2020 | 9093 | 0.210 |
Why?
| Spleen | 2 | 2017 | 486 | 0.210 |
Why?
| Capillary Leak Syndrome | 2 | 2012 | 13 | 0.200 |
Why?
| Arachidonate 12-Lipoxygenase | 1 | 2021 | 13 | 0.200 |
Why?
| Arachidonate 15-Lipoxygenase | 1 | 2021 | 16 | 0.200 |
Why?
| Nephritis | 1 | 2021 | 20 | 0.200 |
Why?
| Propensity Score | 2 | 2019 | 224 | 0.190 |
Why?
| Ureteral Obstruction | 1 | 2021 | 54 | 0.190 |
Why?
| Drug Delivery Systems | 3 | 2016 | 296 | 0.190 |
Why?
| Autophagy-Related Proteins | 1 | 2021 | 39 | 0.180 |
Why?
| Kidney Tubules | 3 | 2012 | 107 | 0.180 |
Why?
| Liver | 2 | 2023 | 1681 | 0.180 |
Why?
| Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 10 | 0.180 |
Why?
| Fibrosis | 3 | 2021 | 454 | 0.180 |
Why?
| Diagnosis, Differential | 2 | 2015 | 1355 | 0.170 |
Why?
| Chemokine CX3CL1 | 3 | 2011 | 21 | 0.170 |
Why?
| Sex Factors | 3 | 2022 | 1721 | 0.170 |
Why?
| Dialysis Solutions | 1 | 2019 | 21 | 0.170 |
Why?
| Kidney Transplantation | 1 | 2005 | 549 | 0.170 |
Why?
| Renal Insufficiency, Chronic | 2 | 2015 | 486 | 0.160 |
Why?
| Biopsy, Needle | 1 | 2019 | 183 | 0.160 |
Why?
| Bronchopulmonary Dysplasia | 1 | 2023 | 330 | 0.160 |
Why?
| Feasibility Studies | 3 | 2017 | 747 | 0.160 |
Why?
| Norwood Procedures | 1 | 2018 | 22 | 0.160 |
Why?
| Random Allocation | 1 | 2019 | 336 | 0.150 |
Why?
| Practice Guidelines as Topic | 2 | 2016 | 1399 | 0.150 |
Why?
| Amino Acid Chloromethyl Ketones | 3 | 2014 | 22 | 0.150 |
Why?
| Delivery of Health Care | 2 | 2015 | 835 | 0.150 |
Why?
| Length of Stay | 5 | 2020 | 951 | 0.150 |
Why?
| Milrinone | 1 | 2018 | 24 | 0.150 |
Why?
| Recovery of Function | 2 | 2019 | 575 | 0.150 |
Why?
| History, 20th Century | 1 | 2019 | 267 | 0.150 |
Why?
| Metabolomics | 2 | 2021 | 527 | 0.150 |
Why?
| Prognosis | 3 | 2014 | 3335 | 0.150 |
Why?
| Hypoplastic Left Heart Syndrome | 1 | 2018 | 110 | 0.140 |
Why?
| Cell Line | 5 | 2021 | 2645 | 0.140 |
Why?
| Immunohistochemistry | 3 | 2019 | 1634 | 0.140 |
Why?
| Hyaluronic Acid | 2 | 2016 | 189 | 0.140 |
Why?
| Survival Rate | 4 | 2018 | 1646 | 0.140 |
Why?
| Postoperative Care | 1 | 2018 | 222 | 0.140 |
Why?
| Cell Cycle Checkpoints | 1 | 2017 | 84 | 0.140 |
Why?
| Blood Pressure | 2 | 2022 | 1539 | 0.140 |
Why?
| Disease Progression | 4 | 2019 | 2389 | 0.140 |
Why?
| Middle Aged | 13 | 2021 | 26831 | 0.140 |
Why?
| CD4 Antigens | 1 | 2017 | 124 | 0.140 |
Why?
| Mice, Mutant Strains | 3 | 2005 | 272 | 0.130 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 242 | 0.130 |
Why?
| Echocardiography | 1 | 2019 | 557 | 0.130 |
Why?
| Endotoxemia | 2 | 2008 | 82 | 0.130 |
Why?
| Hemodialysis Units, Hospital | 1 | 2015 | 5 | 0.130 |
Why?
| Risk Assessment | 4 | 2019 | 2976 | 0.130 |
Why?
| Quinolines | 2 | 2014 | 129 | 0.130 |
Why?
| Heart | 1 | 2019 | 610 | 0.120 |
Why?
| Patient Isolation | 1 | 2015 | 18 | 0.120 |
Why?
| Developed Countries | 1 | 2015 | 28 | 0.120 |
Why?
| Contraindications | 1 | 2015 | 86 | 0.120 |
Why?
| Transforming Growth Factor beta | 2 | 2015 | 448 | 0.120 |
Why?
| Africa | 1 | 2015 | 95 | 0.120 |
Why?
| Ebolavirus | 1 | 2015 | 34 | 0.120 |
Why?
| Equipment Contamination | 1 | 2015 | 54 | 0.120 |
Why?
| Mice, Transgenic | 5 | 2011 | 1955 | 0.120 |
Why?
| Quality Improvement | 2 | 2019 | 953 | 0.120 |
Why?
| Interleukin-1alpha | 1 | 2014 | 55 | 0.120 |
Why?
| Delayed-Action Preparations | 1 | 2015 | 159 | 0.120 |
Why?
| Cardiovascular Diseases | 2 | 2019 | 1729 | 0.120 |
Why?
| Nitric Oxide | 3 | 2008 | 827 | 0.110 |
Why?
| Anticoagulants | 2 | 2015 | 546 | 0.110 |
Why?
| Travel | 1 | 2015 | 121 | 0.110 |
Why?
| Up-Regulation | 1 | 2017 | 812 | 0.110 |
Why?
| Myocardium | 1 | 2019 | 922 | 0.110 |
Why?
| Kinetics | 1 | 2017 | 1558 | 0.110 |
Why?
| Calpain | 4 | 2006 | 53 | 0.110 |
Why?
| Oncogene Proteins | 1 | 2013 | 53 | 0.110 |
Why?
| Bronchoalveolar Lavage Fluid | 2 | 2013 | 590 | 0.110 |
Why?
| Adolescent | 7 | 2020 | 17866 | 0.110 |
Why?
| Workload | 1 | 2014 | 132 | 0.110 |
Why?
| Age Factors | 3 | 2018 | 2894 | 0.110 |
Why?
| Interleukins | 2 | 2011 | 236 | 0.110 |
Why?
| Inflammatory Bowel Diseases | 1 | 2017 | 288 | 0.100 |
Why?
| Child | 7 | 2020 | 18409 | 0.100 |
Why?
| Receptors, Interleukin-8B | 1 | 2012 | 23 | 0.100 |
Why?
| Albumins | 1 | 2013 | 89 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 797 | 0.100 |
Why?
| Podocytes | 1 | 2013 | 44 | 0.100 |
Why?
| Hydrogels | 2 | 2016 | 575 | 0.100 |
Why?
| Antibodies | 2 | 2012 | 372 | 0.100 |
Why?
| Disease Outbreaks | 1 | 2015 | 309 | 0.100 |
Why?
| Endocytosis | 1 | 2013 | 151 | 0.100 |
Why?
| B-Lymphocytes | 1 | 2017 | 772 | 0.100 |
Why?
| Flow Cytometry | 3 | 2011 | 1084 | 0.100 |
Why?
| Ambulatory Care | 1 | 2015 | 478 | 0.100 |
Why?
| Toll-Like Receptor 2 | 1 | 2012 | 109 | 0.100 |
Why?
| Cold Temperature | 3 | 2011 | 129 | 0.100 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 955 | 0.100 |
Why?
| Anti-Inflammatory Agents | 1 | 2015 | 451 | 0.100 |
Why?
| Complement Factor B | 1 | 2012 | 100 | 0.100 |
Why?
| Heart Defects, Congenital | 1 | 2018 | 665 | 0.100 |
Why?
| Trachea | 1 | 2013 | 234 | 0.090 |
Why?
| Radiography | 1 | 2014 | 827 | 0.090 |
Why?
| MicroRNAs | 1 | 2017 | 603 | 0.090 |
Why?
| Organ Preservation | 1 | 2011 | 67 | 0.090 |
Why?
| Caspase 8 | 3 | 2005 | 43 | 0.090 |
Why?
| Nitric Oxide Synthase Type II | 2 | 2008 | 157 | 0.090 |
Why?
| Patient Selection | 4 | 2019 | 646 | 0.090 |
Why?
| Continuity of Patient Care | 1 | 2013 | 253 | 0.090 |
Why?
| Chemokines | 2 | 2008 | 213 | 0.090 |
Why?
| Ultrasonography | 1 | 2014 | 636 | 0.090 |
Why?
| Neutrophils | 2 | 2007 | 1164 | 0.090 |
Why?
| Patient Care Team | 1 | 2015 | 515 | 0.090 |
Why?
| Analysis of Variance | 1 | 2013 | 1229 | 0.090 |
Why?
| Immunoblotting | 3 | 2005 | 282 | 0.090 |
Why?
| L-Lactate Dehydrogenase | 2 | 2007 | 107 | 0.090 |
Why?
| Bleomycin | 1 | 2011 | 228 | 0.090 |
Why?
| Survivors | 1 | 2013 | 410 | 0.090 |
Why?
| Research Design | 1 | 2015 | 930 | 0.090 |
Why?
| Polycystic Kidney Diseases | 2 | 2007 | 55 | 0.080 |
Why?
| Toll-Like Receptor 4 | 1 | 2012 | 286 | 0.080 |
Why?
| Complement Activation | 1 | 2012 | 340 | 0.080 |
Why?
| Aged | 8 | 2021 | 19122 | 0.080 |
Why?
| Proto-Oncogene Proteins | 1 | 2013 | 609 | 0.080 |
Why?
| Monocytes | 1 | 2011 | 503 | 0.080 |
Why?
| Hepatitis A Virus Cellular Receptor 1 | 2 | 2019 | 35 | 0.080 |
Why?
| NF-kappa B | 2 | 2013 | 637 | 0.080 |
Why?
| Dendritic Cells | 1 | 2012 | 436 | 0.080 |
Why?
| Macrophages, Peritoneal | 1 | 2009 | 91 | 0.080 |
Why?
| Fluid Therapy | 1 | 2009 | 122 | 0.080 |
Why?
| Pulmonary Fibrosis | 1 | 2011 | 323 | 0.080 |
Why?
| CD11b Antigen | 4 | 2009 | 58 | 0.080 |
Why?
| Case-Control Studies | 2 | 2019 | 3015 | 0.080 |
Why?
| Mass Screening | 1 | 2015 | 1012 | 0.080 |
Why?
| Caspase 9 | 2 | 2004 | 48 | 0.080 |
Why?
| Capillary Permeability | 1 | 2008 | 135 | 0.070 |
Why?
| Receptors, Chemokine | 1 | 2007 | 43 | 0.070 |
Why?
| Urothelium | 1 | 2008 | 33 | 0.070 |
Why?
| RNA, Messenger | 4 | 2009 | 2563 | 0.070 |
Why?
| Endpoint Determination | 3 | 2012 | 69 | 0.070 |
Why?
| Water-Electrolyte Balance | 2 | 2018 | 26 | 0.070 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 103 | 0.070 |
Why?
| Databases, Factual | 1 | 2011 | 1132 | 0.070 |
Why?
| Adult | 7 | 2021 | 30658 | 0.070 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 349 | 0.070 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 331 | 0.070 |
Why?
| Treatment Outcome | 2 | 2019 | 9123 | 0.070 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 400 | 0.070 |
Why?
| Cell Hypoxia | 1 | 2007 | 220 | 0.070 |
Why?
| Genes, T-Cell Receptor alpha | 1 | 2005 | 11 | 0.060 |
Why?
| Enzyme Inhibitors | 2 | 2008 | 752 | 0.060 |
Why?
| Pilot Projects | 3 | 2018 | 1375 | 0.060 |
Why?
| Liver Transplantation | 1 | 2013 | 774 | 0.060 |
Why?
| Albuminuria | 2 | 2019 | 164 | 0.060 |
Why?
| Survival Analysis | 2 | 2019 | 1211 | 0.060 |
Why?
| Insulin Resistance | 1 | 2013 | 1077 | 0.060 |
Why?
| Odds Ratio | 2 | 2018 | 957 | 0.060 |
Why?
| Polycystic Kidney, Autosomal Dominant | 2 | 2005 | 209 | 0.060 |
Why?
| Young Adult | 3 | 2017 | 10498 | 0.060 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2004 | 45 | 0.060 |
Why?
| Rats | 4 | 2023 | 4973 | 0.060 |
Why?
| Tomography, X-Ray Computed | 1 | 2013 | 2341 | 0.060 |
Why?
| Cytosol | 1 | 2004 | 208 | 0.060 |
Why?
| Myocardial Ischemia | 1 | 2005 | 236 | 0.060 |
Why?
| Colorado | 3 | 2019 | 4089 | 0.050 |
Why?
| Cell Proliferation | 2 | 2007 | 2191 | 0.050 |
Why?
| Contrast Media | 2 | 2016 | 369 | 0.050 |
Why?
| Magnetic Resonance Imaging | 1 | 2014 | 3118 | 0.050 |
Why?
| United States | 3 | 2015 | 12227 | 0.050 |
Why?
| Gene Expression Regulation | 2 | 2013 | 2329 | 0.050 |
Why?
| Brain Ischemia | 1 | 2005 | 297 | 0.050 |
Why?
| Comorbidity | 2 | 2019 | 1457 | 0.050 |
Why?
| Lipoxygenase Inhibitors | 1 | 2021 | 36 | 0.050 |
Why?
| Sample Size | 2 | 2012 | 112 | 0.050 |
Why?
| Kidney Glomerulus | 2 | 2013 | 100 | 0.050 |
Why?
| Stroke | 2 | 2019 | 1015 | 0.050 |
Why?
| Cellular Microenvironment | 1 | 2021 | 78 | 0.050 |
Why?
| Cells, Cultured | 4 | 2012 | 3896 | 0.050 |
Why?
| Statistics as Topic | 2 | 2012 | 298 | 0.050 |
Why?
| Platelet Count | 1 | 2021 | 83 | 0.050 |
Why?
| Animals, Newborn | 1 | 2023 | 778 | 0.050 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 55 | 0.050 |
Why?
| Mice, Inbred BALB C | 2 | 2015 | 1153 | 0.050 |
Why?
| Obesity | 1 | 2013 | 2524 | 0.050 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 95 | 0.040 |
Why?
| Lysosomes | 1 | 2021 | 123 | 0.040 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2023 | 499 | 0.040 |
Why?
| Leukocytes | 1 | 2021 | 277 | 0.040 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 157 | 0.040 |
Why?
| Bicarbonates | 1 | 2020 | 41 | 0.040 |
Why?
| Incidence | 2 | 2018 | 2318 | 0.040 |
Why?
| Matched-Pair Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| Netrin-1 | 1 | 2019 | 11 | 0.040 |
Why?
| Trefoil Factor-3 | 1 | 2019 | 5 | 0.040 |
Why?
| Clusterin | 1 | 2019 | 10 | 0.040 |
Why?
| beta 2-Microglobulin | 1 | 2019 | 45 | 0.040 |
Why?
| Hospitals, University | 1 | 2019 | 170 | 0.040 |
Why?
| Cystatin C | 1 | 2019 | 62 | 0.040 |
Why?
| Hospitalization | 2 | 2018 | 1755 | 0.040 |
Why?
| Signal Transduction | 3 | 2021 | 4525 | 0.040 |
Why?
| Fatty Acid-Binding Proteins | 1 | 2019 | 61 | 0.040 |
Why?
| Age Distribution | 1 | 2019 | 340 | 0.040 |
Why?
| Sex Distribution | 1 | 2019 | 335 | 0.040 |
Why?
| Substance Abuse, Intravenous | 1 | 2019 | 99 | 0.040 |
Why?
| Zebrafish | 1 | 2022 | 411 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2019 | 250 | 0.040 |
Why?
| Models, Theoretical | 1 | 2022 | 517 | 0.040 |
Why?
| Exosomes | 1 | 2019 | 91 | 0.040 |
Why?
| Drug Administration Schedule | 1 | 2019 | 719 | 0.040 |
Why?
| Cardiotonic Agents | 1 | 2018 | 119 | 0.040 |
Why?
| Thoracic Surgery | 1 | 2018 | 105 | 0.030 |
Why?
| Immunocompromised Host | 1 | 2018 | 196 | 0.030 |
Why?
| Decision Trees | 1 | 2016 | 81 | 0.030 |
Why?
| Colitis, Ulcerative | 1 | 2017 | 105 | 0.030 |
Why?
| Heterozygote | 2 | 2007 | 251 | 0.030 |
Why?
| Sodium Bicarbonate | 1 | 2015 | 40 | 0.030 |
Why?
| Free Radical Scavengers | 1 | 2015 | 78 | 0.030 |
Why?
| Caspase 2 | 2 | 2006 | 14 | 0.030 |
Why?
| Cohort Studies | 2 | 2018 | 4904 | 0.030 |
Why?
| Erythropoietin | 1 | 2015 | 72 | 0.030 |
Why?
| Early Diagnosis | 1 | 2016 | 218 | 0.030 |
Why?
| Reimbursement Mechanisms | 1 | 2015 | 77 | 0.030 |
Why?
| In Situ Nick-End Labeling | 2 | 2005 | 119 | 0.030 |
Why?
| Acetylcysteine | 1 | 2015 | 142 | 0.030 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 191 | 0.030 |
Why?
| Protective Agents | 1 | 2014 | 38 | 0.030 |
Why?
| Interprofessional Relations | 1 | 2016 | 251 | 0.030 |
Why?
| Interleukin-1 | 2 | 2012 | 970 | 0.030 |
Why?
| Antioxidants | 2 | 2008 | 530 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2017 | 6357 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 2815 | 0.030 |
Why?
| Lipopolysaccharides | 1 | 2017 | 817 | 0.030 |
Why?
| Crohn Disease | 1 | 2017 | 196 | 0.030 |
Why?
| Smoking | 1 | 2019 | 1392 | 0.030 |
Why?
| Health Policy | 1 | 2015 | 334 | 0.030 |
Why?
| Clodronic Acid | 1 | 2012 | 8 | 0.030 |
Why?
| Cost of Illness | 1 | 2014 | 254 | 0.030 |
Why?
| Global Health | 1 | 2014 | 288 | 0.020 |
Why?
| Diphtheria Toxin | 1 | 2012 | 51 | 0.020 |
Why?
| Diet, High-Fat | 1 | 2013 | 225 | 0.020 |
Why?
| Chemokine CCL2 | 1 | 2012 | 105 | 0.020 |
Why?
| Diabetes Mellitus | 1 | 2019 | 906 | 0.020 |
Why?
| Lung Compliance | 1 | 2011 | 49 | 0.020 |
Why?
| Interleukin-33 | 1 | 2011 | 38 | 0.020 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 140 | 0.020 |
Why?
| Immunotherapy | 1 | 2015 | 474 | 0.020 |
Why?
| Postoperative Period | 1 | 2012 | 292 | 0.020 |
Why?
| Trauma Severity Indices | 1 | 2011 | 111 | 0.020 |
Why?
| Informed Consent | 1 | 2012 | 161 | 0.020 |
Why?
| Medicare | 1 | 2015 | 666 | 0.020 |
Why?
| Guideline Adherence | 1 | 2014 | 492 | 0.020 |
Why?
| Algorithms | 1 | 2017 | 1489 | 0.020 |
Why?
| Patient Acceptance of Health Care | 1 | 2015 | 679 | 0.020 |
Why?
| Collagen | 1 | 2011 | 416 | 0.020 |
Why?
| Body Weight | 1 | 2013 | 873 | 0.020 |
Why?
| Liver Diseases | 1 | 2011 | 259 | 0.020 |
Why?
| Thiocarbamates | 1 | 2008 | 6 | 0.020 |
Why?
| Chromones | 1 | 2008 | 35 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2013 | 1715 | 0.020 |
Why?
| Adoptive Transfer | 1 | 2009 | 198 | 0.020 |
Why?
| Attitude of Health Personnel | 1 | 2015 | 976 | 0.020 |
Why?
| GTP Cyclohydrolase | 1 | 2008 | 7 | 0.020 |
Why?
| Amidines | 1 | 2008 | 16 | 0.020 |
Why?
| Benzylamines | 1 | 2008 | 39 | 0.020 |
Why?
| Cyclic N-Oxides | 1 | 2008 | 30 | 0.020 |
Why?
| Proline | 1 | 2008 | 72 | 0.020 |
Why?
| CX3C Chemokine Receptor 1 | 1 | 2007 | 18 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2009 | 396 | 0.020 |
Why?
| Antimycin A | 1 | 2007 | 13 | 0.020 |
Why?
| Health Promotion | 1 | 2014 | 686 | 0.020 |
Why?
| Renal Circulation | 1 | 2008 | 53 | 0.020 |
Why?
| Spin Labels | 1 | 2008 | 48 | 0.020 |
Why?
| Cell Count | 1 | 2008 | 304 | 0.020 |
Why?
| Morpholines | 1 | 2008 | 102 | 0.020 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2007 | 54 | 0.020 |
Why?
| von Willebrand Factor | 1 | 2007 | 56 | 0.020 |
Why?
| Rats, Inbred Strains | 1 | 2007 | 376 | 0.020 |
Why?
| Sex Characteristics | 1 | 2011 | 635 | 0.020 |
Why?
| MAP Kinase Signaling System | 1 | 2008 | 276 | 0.020 |
Why?
| RNA, Catalytic | 1 | 2007 | 182 | 0.020 |
Why?
| Epithelial Cells | 1 | 2012 | 956 | 0.020 |
Why?
| Acrylates | 1 | 2006 | 45 | 0.020 |
Why?
| Cysteine Endopeptidases | 1 | 2006 | 60 | 0.020 |
Why?
| Killer Cells, Natural | 1 | 2009 | 383 | 0.020 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 249 | 0.020 |
Why?
| Acute Disease | 1 | 2008 | 915 | 0.020 |
Why?
| Cathepsin B | 1 | 2005 | 14 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2013 | 2799 | 0.020 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2006 | 172 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2005 | 49 | 0.020 |
Why?
| Caspase 7 | 1 | 2005 | 22 | 0.020 |
Why?
| Inhibitory Concentration 50 | 1 | 2005 | 75 | 0.020 |
Why?
| Cell Survival | 1 | 2008 | 1022 | 0.020 |
Why?
| Fas Ligand Protein | 1 | 2005 | 58 | 0.020 |
Why?
| Thermosensing | 1 | 2004 | 10 | 0.020 |
Why?
| Wounds and Injuries | 1 | 2012 | 723 | 0.010 |
Why?
| Kidney Cortex | 1 | 2004 | 23 | 0.010 |
Why?
| DNA Fragmentation | 1 | 2004 | 47 | 0.010 |
Why?
| Sialoglycoproteins | 1 | 2005 | 158 | 0.010 |
Why?
| Microvilli | 1 | 2004 | 70 | 0.010 |
Why?
| Animals, Genetically Modified | 1 | 2005 | 215 | 0.010 |
Why?
| Mitochondrial Proteins | 1 | 2006 | 220 | 0.010 |
Why?
| Perfusion | 1 | 2004 | 151 | 0.010 |
Why?
| Cross-Sectional Studies | 1 | 2014 | 4411 | 0.010 |
Why?
| Interleukin 1 Receptor Antagonist Protein | 1 | 2005 | 254 | 0.010 |
Why?
| Cell Movement | 1 | 2007 | 866 | 0.010 |
Why?
| Membrane Glycoproteins | 1 | 2005 | 429 | 0.010 |
Why?
| Surveys and Questionnaires | 1 | 2014 | 4631 | 0.010 |
Why?
| Rats, Sprague-Dawley | 1 | 2007 | 2212 | 0.010 |
Why?
| Carrier Proteins | 1 | 2006 | 696 | 0.010 |
Why?
| Temperature | 1 | 2004 | 578 | 0.010 |
Why?
| Endothelium, Vascular | 1 | 2007 | 850 | 0.010 |
Why?
|
|
Faubel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) Derived automatically from this person's publications. _
Co-Authors ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People in Profiles who have published with this person. _
Similar People ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors ![Expand Description](https://profiles.ucdenver.edu/Framework/Images/info.png) People whose addresses are nearby this person. _
|